Risk stratification and treatment of primary biliary cholangitis

被引：2
作者：
Martinez, Javier [1 ,2 ,3 ,4 ]
Aguilera, Lara [1 ,2 ,3 ]
Albillos, Agustin [1 ,2 ,3 ,4 ]
机构：
[1] Hosp Univ Ramon y Cajal, Hepatol & Gastroenterol Dept, Ctra Colmenar Viejo,Km 9-100, Madrid 28034, Spain
[2] Univ Alcala, Madrid, Spain
[3] IRYCIS, Madrid, Spain
[4] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
来源：
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS | 2019年 / 111卷 / 01期
关键词：
Cirrhosis; Ursodeoxycholic acid; Obeticholic acid; Fibrates; Budesonide; URSODEOXYCHOLIC-ACID THERAPY; LIVER FIBROSIS PROGRESSION; OBETICHOLIC ACID; BIOCHEMICAL RESPONSE; BACTERIAL TRANSLOCATION; END-POINTS; CIRRHOSIS; BEZAFIBRATE; PROGNOSIS; DISEASES;
D O I：
10.17235/reed.2018.5662/2018
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Primary biliary cholangitis is a chronic liver disorder characterized by progressive cholestasis that may evolve to liver cirrhosis. While ursodeoxycholic acid is the treatment of choice, around 30% of patients do not respond to this therapy. These patients have a poorer prognosis, hence should be identified early in order to be offered therapy options. Along these lines, improved understanding of the condition's pathophysiology has allowed the development of newer drugs, including obeticholic acid and fibrates. This review offers a perspective on risk stratification and treatment for these patients, from ursodeoxycholic acid to second-line treatments.
引用
收藏
页码：63 / 70
页数：8
相关论文
共 68 条
  • [1] Obeticholic acid for the treatment of primary biliary cholangitis
    Ali, Ahmad H.
    Lindor, Keith D.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (13) : 1809 - 1815
  • [2] Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid
    Angulo, P
    Jorgensen, RA
    Keach, JC
    Dickson, ER
    Smith, C
    Lindor, KD
    [J]. HEPATOLOGY, 2000, 31 (02) : 318 - 323
  • [3] Angulo P, 2001, AM J GASTROENTEROL, V96, P3152
  • [4] Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid
    Angulo, P
    Lindor, KD
    Therneau, TM
    Jorgensen, RA
    Malinchoc, M
    Kamath, PS
    Dickson, ER
    [J]. LIVER, 1999, 19 (02): : 115 - 121
  • [5] Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid
    Boberg, K. M.
    Wisloff, T.
    Kjollesdal, K. S.
    Stovring, H.
    Kristiansen, I. S.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (07) : 794 - 803
  • [6] Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review
    Boonstra, Kirsten
    Beuers, Ulrich
    Ponsioen, Cyriel Y.
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 (05) : 1181 - 1188
  • [7] Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC)
    Bowlus, C.
    Pockros, P.
    Kremer, A. E.
    Pares, A.
    Forman, L.
    Drenth, J. P.
    Ryder, S.
    Malecha, E. S.
    Pencek, R.
    Iloeje, U.
    Macconell, L.
    Shapiro, D.
    Pierre, B.
    [J]. JOURNAL OF HEPATOLOGY, 2018, 68 : S111 - S112
  • [8] The UK-PBC Risk Scores: Derivation and Validation of a Scoring System for Long-Term Prediction of End-Stage Liver Disease in Primary Biliary Cholangitis
    Carbone, Marco
    Sharp, Stephen J.
    Flack, Steve
    Paximadas, Dimitrios
    Spiess, Kelly
    Adgey, Carolyn
    Griffiths, Laura
    Lim, Reyna
    Trembling, Paul
    Williamson, Kate
    Wareham, Nick J.
    Aldersley, Mark
    Bathgate, Andrew
    Burroughs, Andrew K.
    Heneghan, Michael A.
    Neuberger, James M.
    Thorburn, Douglas
    Hirschfield, Gideon M.
    Cordell, Heather J.
    Alexander, Graeme J.
    Jones, David E. J.
    Sandford, Richard N.
    Mells, George F.
    [J]. HEPATOLOGY, 2016, 63 (03) : 930 - 950
  • [9] Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid
    Carbone, Marco
    Mells, George F.
    Pells, Greta
    Dawwas, Muhammad F.
    Newton, Julia L.
    Heneghan, Michael A.
    Neuberger, James M.
    Day, Darren B.
    Ducker, Samantha J.
    Sandford, Richard N.
    Alexander, Graeme J.
    Jones, David E. J.
    [J]. GASTROENTEROLOGY, 2013, 144 (03) : 560 - +
  • [10] Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes
    Cheung, A. C.
    Lapointe-Shaw, L.
    Kowgier, M.
    Meza-Cardona, J.
    Hirschfield, G. M.
    Janssen, H. L. A.
    Feld, J. J.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (02) : 283 - 293
1234567